ArticleProceedings (Baylor University. Medical Center)2026
Patient outcomes following extracorporeal membrane oxygenation support for severe COVID-19 acute respiratory distress syndrome.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discordance between recovery and quality of life after ECMO for severe COVID-19.Proceedings (Baylor University. Medical Center) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough patients treated with extracorporeal membrane oxygenation (ECMO) can have reduced long-term lung function, impaired quality of life, and high rates of posttraumatic stress disorder, data on patients with severe COVID-19 requiring ECMO are limited. We undertook a prospective study of our post-COVID ECMO population to assess long-term lung function and quality of life.
methodsFor patients with COVID who required ECMO support, survival, pulmonary function, spirometry, arterial blood gas, and patient quality of life were assessed.
resultsTwelve patients completed follow-up at a median of 674.5 days. Pulmonary function testing, reported as median percentage of predicted, was as follows: forced vital capacity (FVC), 73.2% (59.8-82); forced expiratory volume over 1 second (FEV1), 72.3% (67.1-88.3); FEV1/FVC, 110% (100-113.1); total lung capacity, 59.3% (50.6-76.7); vital capacity, 75% (57.5-85.3); and diffusing capacity of the lungs for carbon monoxide, 84.5% (71.9-87.4). Arterial blood gas at follow up was pH 7.41 (7.41-7.43); partial pressure of carbon dioxide, 40 mm Hg (39-42); partial pressure of oxygen, 81 mm Hg (76-83); and arterial oxygen saturation, 96% (95-96). The median Short-Form Kansas City Cardiomyopathy Questionnaire overall summary score was 88.8 (72.1-94.8). The Rand Short Form 36 scores were markedly reduced.
conclusionThese findings suggest that patients who required ECMO for COVID-related acute respiratory distress syndrome achieved improvement in objective lung function over time, despite persistent functional limitations. Patients also reported decreased self-reported quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.